Circassia Pharmaceuticals
A specialty biopharmaceutical company developing novel immunotherapies for allergy including cat, grass, ragweed & house dust mite.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
* | N/A | Post IPO Equity | |
| Total Funding | 000k | ||
| GBP | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (39 %) | 11 % | 19 % | 14 % | 13 % | 11 % | 10 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 4 % | 23 % | 31 % | 33 % | 34 % | 35 % | 36 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 14 % | 52 % | 29 % | 9 % | 23 % | 25 % | 28 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Circassia is a specialty pharmaceutical company focused on providing advanced asthma management solutions. The company operates in the healthcare sector, primarily serving physicians and healthcare providers globally. Circassia's core product is the NIOX device, which measures fractional exhaled nitric oxide (FeNO) levels in patients' breath to assess airway inflammation, a key indicator in asthma management. This technology enables healthcare professionals to make more informed decisions regarding asthma treatment and monitoring.
Circassia's business model revolves around the development, manufacturing, and distribution of its NIOX devices. The company generates revenue through the sale of these devices and associated consumables, as well as through service agreements and support packages. By focusing on a niche market within respiratory care, Circassia has positioned itself as a leader in point-of-care FeNO monitoring.
The company operates in a competitive market but differentiates itself through its specialized technology and commitment to improving patient outcomes. Circassia's clients include hospitals, clinics, and individual healthcare practitioners who require accurate and reliable tools for asthma management.
Keywords: FeNO monitoring, asthma management, healthcare, specialty pharmaceutical, respiratory care, NIOX device, airway inflammation, point-of-care, medical devices, patient outcomes.
